Backing Down On Forward Funding? HHS Now Says It Won’t Make Multiple Year Awards Until September
In Brief: AACR Lectures Listed; Winn Heads Community Oncology At MDA; Henderson ACS Grant Renewed
FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin
B.J. Kennedy Receives ACCC Award, Says More Medical Oncologists Are Still Needed
Trombold Tells How Scripps Raises Money for Cancer Center, Gets Independent From “Whiny Administrator”
McKenna Sees Budget Cuts as Threat to Year 2000 Goals Urges Stepped Up Efforts Against Tobacco Industry
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
